WEBINARS

​

Free public webinar series presented by leading medicines policy researchers. The webinars aim to make recent, policy-relevant research more accessible to a global public audience and facilitate flows of knowledge between the research and policy & practice communities.

​

​

​

Past webinars (recordings and materials available on links)

​

March 2020 | Dzintars Gotham, Independent researcher; Lindsay McKenna, Treatment Action Group (TAG)

• How much does it cost to develop a new medicine? Public versus private investments in the TB drug bedaquiline

 

 

February 2020 | Suerie Moon, Global Health Centre, Graduate Institute of Geneva; Tania Cernuschi, World Health Organization

• Fair pricing of medicines: what lessons from growing transparency in vaccines prices?

​​

 

December 2019 | Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board (PMPRB), Canada

• Regulating drug prices: national and global implications of Canada’s recent reforms

​

​

November 2019 | Slavek Roller, Faculty of Economics and Business, Goethe University Frankfurt; Nadya Wells, Global Health Centre, Graduate Institute of Geneva

• Public Funding of Biomedical R&D: What Role for Public Investment Funds and Financial Markets?

​

​

October 2019 | Peter Yu, Center for Law and Intellectual Property at Texas A&M University; Yuanqiong Hu, Access Campaign of Médecins Sans Frontières (MSF)

• China’s changing role in the global pharmaceutical system: implications for national and global public health

​

​

September 2019 | Reed Beall, University of Calgary; Mayra Vasquez,  National College of Pharmaceutical Chemists of Colombia; Miguel Cortes,  UNOPS (United Nations Office for Project Services)

• Is Data Exclusivity Justified? Evidence on the Impacts on Innovation and Access to Medicines​

​

​

June 2019 | Marg Ewen and Molly Lepeska, Health Action International

• Global access to affordable insulin: understanding the barriers

​

​

April 2019 | Ekaterina Cleary, Bentley University

• Public funding of drug development: contributions of the US NIH

​

​

March 2019 | Kiu Tay-Teo, World Health Organization

• R&D costs of cancer medicines: how does it compare with sales income?

​

​

February 2019 | Carolina Gomez, INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia’s National Institute of Food and Drug Monitoring)

• Regulation to accelerate access to biosimilars: Colombia's pioneering approach

​

​

January 2019 | Fred Abbott, Florida State University College of Law

• Using competition law to address high medicines prices

​

​

December 2018 | Sabine Vogler, Austrian Public Health Institute (GÖG)

• Addressing high drug prices - what can be learned from European policies?

​

​

November 2018 | Gavin Yamey, Duke University

• New technologies for neglected diseases: what is likely to come out of the pipeline, what is missing, and what will it cost?

​

​

October 2018 | Achal Prabhala, accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa

• A New World Patent Order: An analysis of granted and rejected biomedical patents in India - with implications for Brazil, South Africa & beyond

​